Processa Pharmaceuticals (PCSA) EBT Margin (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly EBT Margin came in at 2632.42% in Q1 2016, down 115989.0% YoY from N/an in Q2 2015, and down 40.27% on a QoQ basis from 1876.7% in Q4 2015.
Processa Pharmaceuticals (PCSA) EBT Margin (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of EBT Margin data on file, last reported at 2632.42% in Q1 2016.
- Quarterly EBT Margin fell 115989.0% year-over-year to 2632.42% in Q1 2016, while the trailing twelve-month figure through Dec 2016 was 6743.58% (down 336127.0% YoY) and the FY2016 annual result came in at 6743.58%, down 411381.0% from the prior year.
- EBT Margin declined to 2632.42% in Q1 2016, from 1876.7% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 489.61% in Q2 2012 to a low of 10420.55% in Q1 2014.
- A 5-year average of 2858.12% and a median of 1488.75% in 2014 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 894802 bps in 2015, down 857337 bps in 2015.
- Tracing PCSA's EBT Margin over 5 years: stood at 2489.3% in 2012, then soared by 54 bps to 1151.2% in 2013, then tumbled by 321 bps to 4848.11% in 2014, then soared by 61 bps to 1876.7% in 2015, then sank by 40 bps to 2632.42% in 2016.
- The last three EBT Margin figures came in at 2632.42% (Q1 2016), 1876.7% (Q4 2015), and 1263.91% (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -2,632.42% |
| Dec 31, 2015 | -1,876.70% |
| Sep 30, 2015 | -1,263.91% |
| Jun 30, 2015 | -9,678.82% |
| Mar 31, 2015 | -1,472.53% |
| Dec 31, 2014 | -4,848.11% |
| Sep 30, 2014 | -1,504.97% |
| Jun 30, 2014 | -1,105.44% |
| Mar 31, 2014 | -10,420.55% |
| Dec 31, 2013 | -1,151.20% |
| Sep 30, 2013 | -570.92% |
| Jun 30, 2013 | -746.89% |
| Mar 31, 2013 | -4,251.90% |
| Dec 31, 2012 | -2,489.30% |
| Sep 30, 2012 | -1,226.67% |
| Jun 30, 2012 | -489.61% |